

External Beam Radiotherapy Services delivered as part of a Radiotherapy Network (Adult) Quality Dashboard 2021/22

Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes (General)	Reporting Periods			
															Q1	Q2	Q3	Q4
RAD12a	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Waiting times	Outcome measure		Number of patients waiting longer than 31 days from decision to treat date to date of first treatment - radical	Of those in the denominator, the number of patients who waited longer than 31 days from decision to treat date to date of first treatment date	The total number of radical patients commencing treatment in the reporting period	Quarterly	Quarterly	PHE	PHE		Lower is better	Include all cancers. Non cancers excluded	Jan 21 - Mar 21	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21
RAD12b	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Waiting times	Outcome measure		Number of patients waiting longer than 31 days from decision to treat date to date of first treatment - palliative	Of those in the denominator, the number of patients who waited longer than 31 days from decision to treat date to date of first treatment date	The total number of palliative patients commencing treatment in the reporting period	Quarterly	Quarterly	PHE	PHE		Lower is better	Include all cancers. Non cancers excluded	Jan 21 - Mar 21	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21
RAD13a	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Activity	Outcome measure		Number of episodes of radical treatment by tumour site - lung, including SABR (Stereotactic Ablative Body Radiotherapy)	Of those in the denominator, the number of episode where treatment was radical	The total number of treatment episodes in the reporting period (lung only, INCLUDING SABR)	Annual	Annual	PHE	PHE		Higher is better		N/A	N/A	N/A	Apr 20 - Mar 21
RAD13b	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Activity	Outcome measure		Number of episodes of radical treatment by tumour site - lung SABR (Stereotactic Ablative Body Radiotherapy) only	Of those in the denominator, the number of episodes where treatment was SABR	The total number of radical treatment episodes in the reporting period (lung only)	Annual	Annual	PHE	PHE		Higher is better	Data pulled using OPCS code Y91.5	N/A	N/A	N/A	Apr 20 - Mar 21
RAD13c	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Activity	Outcome measure		Number of episodes of radical treatment by tumour site - head and neck only	Of those in the denominator, the number of episode where treatment was radical	The total number of treatment episodes in the reporting period (head and neck only)	Annual	Annual	PHE	PHE		Higher is better		N/A	N/A	N/A	Apr 20 - Mar 21
RAD13d	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Activity	Outcome measure		Number of episodes of radical treatment by tumour site - cervix	Of those in the denominator, the number of episode where treatment was radical	The total number of treatment episodes in the reporting period (cervix only)	Annual	Annual	PHE	PHE		Higher is better	Data pulled using ICD 10 code C53	N/A	N/A	N/A	Apr 20 - Mar 21
RAD14	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	IMRT	Process measure		Proportion of all Radiotherapy Radical episodes receiving Inverse Planned IMRT (excluding breast)	Of those in the denominator, the number of episodes where the patient received Inverse Planned IMRT	The total number of new treatment episodes where intent was radical in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Use delivery OPCS X671. Exclude breast cancer, brachytherapy and non melanoma (C44) in the numerator and brachytherapy and non melanoma in the denominator.	Jan 21 - Mar 21	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21
RAD15a	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Image guidance	Process measure	Proxy measure to see improvement in this treatment and avoidance of side effects	Proportion of radical lung patients treated using image guidance	Of those in the denominator, the number of episodes where patient was treated using image guidance	The total number of lung episodes in the reporting period	Annual	Annual	PHE	PHE	50%	Higher is better		N/A	N/A	N/A	Apr 20 - Mar 21
RAD15b	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Image guidance	Process measure	Proxy measure to see improvement in this treatment and avoidance of side effects	Proportion of radical prostate patients treated using image guidance	Of those in the denominator, the number of episodes where patient was treated using image guidance	The total number of prostate episodes in the reporting period	Annual	Annual	PHE	PHE	50%	Higher is better		N/A	N/A	N/A	Apr 20 - Mar 21
RAD15c	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Image guidance	Process measure	Proxy measure to see improvement in this treatment and avoidance of side effects	Proportion of radical head and neck patients treated using image guidance	Of those in the denominator, the number of episodes where patient was treated using image guidance	The total number of head and neck episodes in the reporting period	Annual	Annual	PHE	PHE	100%	Higher is better		N/A	N/A	N/A	Apr 20 - Mar 21
RAD16	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Waiting times	Outcome measure	Mean number of days	Mean waiting time (in days) from date of referral to radiotherapy department to the date of treatment commencing for Category 1 patients	Of those in the denominator, the total number of days waited from date of referral to RT dept to date of treatment commencing	The total number of patients commencing treatment in the reporting period	Quarterly	Quarterly	PHE	PHE		Lower is better	Category 1 patients - Squamous cell carcinoma head and neck, cervix, vagina and vulva, anus., all radical lung, all radical oesophagus	Jan 21 - Mar 21	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21
RAD17	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Breast cancer radiotherapy	Outcome measure		Proportion of patients for whom radiotherapy is indicated as part of treatment for breast cancer less than or equal to 15 fractions (excluding any boost)	Of those in the denominator, the number where the radiotherapy is less than or equal to 15 fractions	The total number of breast cancer patients receiving radiotherapy in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Teletherapy only. Excludes electrons	Jan 21 - Mar 21	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21
RAD18	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Metastatic bone radiotherapy	Outcome measure		Proportion of metastatic bone radiotherapy episodes treated with a single fraction of external beam radiotherapy	Of those in the denominator, the number where external beam radiotherapy treated with a single fraction	The total number of metastatic bone radiotherapy episodes in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Excludes spinal cord compression	Jan 21 - Mar 21	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21

Indicator Reference Number	Domain	Theme	Measure	Rationale	Name of Indicator / Description	Numerator	Denominator	Period Type	Frequency	Data Source Numerator	Data Source Denominator	Target	Interpretation Guidance	Notes (General)	Reporting Periods			
															Q1	Q2	Q3	Q4
RAD19	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Prostate cancer radiotherapy	Outcome measure		Proportion of prostate cancer patients treated with radical external beam radiotherapy using 5, 19 or 20 fractions of treatment	Of those in the denominator, the number where external beam radiotherapy is 5,19 or 20 fractions	The total number of prostate cancer patients receiving radical radiotherapy (5,19 20 or more) in the reporting period	Quarterly	Quarterly	PHE	PHE		Higher is better	Teletherapy only include all patients	Jan 21 - Mar 21	Apr 21 - Jun 21	Jul 21 - Sep 21	Oct 21 - Dec 21
RAD20	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Fractions per linac	Process measure		Departmental average number of fractions per linac	The total number of fractions	The total number of linacs	Annual	Annual	PHE	PHE		Higher is better		N/A	N/A	N/A	Apr 20 - Mar 21
RAD21	Domain 5: Treating and caring for people in a safe environment; and protecting them from avoidable harm	Trials	Process measure		Proportion of patients recruited to trials	Of those in the denominator, the number who are recruited to a trial	The total number of patients receiving treatment in the reporting period	Annual	Annual	Provider submitted data	Provider submitted data		Higher is better		N/A	N/A	N/A	Apr 20 - Mar 21
Data collection has been approved by the Review of Central Returns - ROCR ROCR/OR/2230/001MAND																		